Nebilet Plus (Hydrochlorothiazide, Nebivolol)

Nebivolol is a selective β1‑adrenergic receptor antagonist. By blocking β1 receptors in the heart, it reduces heart rate and contractility, decreasing cardiac output. In addition, nebivolol stimulates endothelial nitric‑oxide synthase, leading to nitric‑oxide release and vasodilation, which further lowers peripheral vascular resistance. This dual action contributes to its antihypertensive effect.

The dosage of Nebilet Plus is individualized by the prescribing clinician based on the patient’s blood pressure, renal function, and concomitant therapies. The prescriber determines the appropriate strength and frequency, which is typically taken once daily with or without food. Patients should follow the exact regimen written on the prescription label.

Safety of Nebilet Plus during pregnancy or lactation has not been fully established. Nebivolol and hydrochlorothiazide cross the placenta and may be excreted in breast milk, potentially affecting the fetus or infant. Healthcare providers usually weigh the benefits against potential risks and may recommend alternative antihypertensive agents when safer options are available.

To request Nebilet Plus, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifying trade or institutional credentials before providing a quotation. The sales team then replies with pricing, availability, shipping details and any necessary import documentation.

Compared with single‑component agents, Nebilet Plus offers the convenience of a fixed‑dose combination of a β1‑blocker and a thiazide diuretic, potentially improving adherence. It provides both heart‑rate reduction and diuretic‑induced volume loss, which can be more effective than monotherapy in patients requiring multiple mechanisms. However, clinicians must consider individual tolerability and the risk of combined side‑effects versus alternative classes such as ACE inhibitors or calcium‑channel blockers.

Nebilet Plus tablets should be stored at room temperature, below 25 °C, in their original blister pack or bottle. They must be kept away from moisture, excessive heat and direct sunlight. Do not store in bathrooms or near kitchen appliances. Keep out of reach of children and dispose of any expired product according to local regulations.

Nebilet Plus is taken orally, usually once daily, with or without food, as directed by the prescribing physician. The tablet should be swallowed whole with a glass of water; it should not be crushed, chewed, or split unless specifically instructed. Consistent timing each day helps maintain stable blood‑pressure control.

The most serious adverse events linked to Nebilet Plus include severe hypotension, electrolyte disturbances such as hyponatraemia or hypokalaemia, acute kidney injury, and rare allergic reactions like angio‑edema. Patients should be educated to recognize symptoms such as dizziness, fainting, rapid weight gain, swelling, or rash, and seek immediate medical attention if they occur.

Nebilet Plus is contraindicated in patients with known hypersensitivity to nebivolol, hydrochlorothiazide, or any excipients in the tablet. It should also be avoided in individuals with severe bradycardia, second‑ or third‑degree atrioventricular block without a pacemaker, uncompensated heart failure, or severe renal impairment. Clinicians must assess each patient’s medical history before initiating therapy.